The pharmaceutical company AstraZeneca has reportedly started negotiations to merge with Bristol Myers Squibb, one of its main competitors. The merger between AstraZeneca and Bristol Myers SquibbThe news of the ongoing negotiations between AstraZeneca and Bristol Myers Squibb was first to report FinancialTimeswhich clarified some fundamental points. If the operation were successful, the fourth pharmaceutical company in the world would be born. What company is Bristol Myers SquibbBMS, on the other hand, has different specializations from those of AstraZeneca. Bristol Myers Squibb performed strongly, with earnings per share of $2.04 in the second quarter and more than $24 billion in revenue in the first half of 2026.